A therapy built on LSD — a drug most people associate with the 1960s counterculture, not the pharmacy — has now succeeded in a second large late-stage trial for anxiety. The result puts Definium Therapeutics on course to seek what would be a landmark: the first approval of a psychedelic medicine for an anxiety disorder.

What the trial found

The study, called Panorama, enrolled 245 participants with generalized anxiety disorder (GAD), randomizing them to a single dose of 100 micrograms of DT120, a lower 50-microgram dose, or placebo, over a 12-week double-blind period. Patients on the 100-microgram dose saw their scores on the Hamilton Anxiety Rating Scale fall by 9.8 points, versus a 4.7-point drop on placebo — a placebo-adjusted improvement of about 5.1 points. Notably, some patients reported changes as early as the second day after dosing.

It is the company’s third positive Phase 3 readout since June. An earlier anxiety study, Voyage, showed an even larger effect — an 11.6-point reduction versus 6.2 for placebo — and the program has also posted positive depression data.

How psychedelic therapy actually works

It is important to understand what “an LSD-based therapy” means in this context. This is not recreational use. In these trials, a single, carefully controlled dose is given in a clinical setting, typically alongside psychological support, and patients are monitored throughout the hours-long experience. The scientific rationale is that psychedelics may temporarily increase the brain’s plasticity — its ability to form new connections — opening a window in which entrenched patterns of anxious thinking can shift. That a benefit appears within days and persists for weeks after a single dose is part of what makes the approach so intriguing to psychiatry.

Why it matters

Generalized anxiety disorder is common, chronic and frequently undertreated; standard options like SSRIs take weeks to work and don’t help everyone. A single-dose treatment with rapid, durable effects would be a genuine departure. More broadly, an approval would mark the maturation of the psychedelic-medicine field from promise to product — a “sea change,” as one report put it — and would force health systems to build the infrastructure (trained supervisors, monitored dosing sessions) that this kind of therapy requires.

The caveats

Several cautions apply. The trials measure symptom scales over 12 weeks; long-term durability and real-world safety still need scrutiny, and psychedelics carry risks (including rare adverse psychological reactions) that make supervised administration essential. Blinding is also notoriously hard in psychedelic trials, since patients often can tell whether they received an active dose — a limitation regulators will weigh. And a positive trial is not an approval: the FDA still has to review the full package. Still, as a scientific and cultural milestone, a psychedelic drug clearing repeated Phase 3 hurdles for anxiety is hard to overstate. This is research and business news, not medical advice.